MSKCC | Strategic Alliance Partners

Latest from MSKCC

SAR439859 Achieves On-Target Activity in Metastatic ER+ Breast Cancer

December 28, 2020

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.

2020 Ushers in Newfound Adjustments, Applications in Lung Cancer

December 02, 2020

Mark G. Kris, MD, discusses the strengths of this year’s New York Lung Cancers Symposium, the advances that have been made over the past year, and potential routes forward in advancing the field of lung cancer.

AL101 Shows Promising Activity in Recurrent/Metastatic Adenoid Cystic Carcinoma With NOTCH Activating Mutations

November 04, 2020

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.